Nautilus trial: what clinicians have said so far
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
- NCT06066437 ↗
- Recruiting
- M.D. Anderson Cancer Center
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on Nautilus (177Lu rhPSMA-10.1; 177Lu rhPSMA-10.1 plus degarelix in prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 15 indexed sources
Automated from all 15 indexed sources (May 2023 – Jan 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether adding ADT to neoadjuvant Lu-177 PSMA is needed before surgery
- Whether and when ADT up-regulates PSMA expression enough to prime Lu-177 PSMA uptake
- Whether Lu-177 PSMA is better given before ADT, in hormone-naive high-risk localized disease
- Which tissue biomarkers from surgery can guide treatment after neoadjuvant Lu-177 PSMA
Indexed commentary on Nautilus so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 posts on X, typically up to 35 once built | |
| 5 YouTube videos, typically up to 22 once built | |
| 2 podcast episodes, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Arm A: 177Lu rhPSMA-10.1; Arm B: 177Lu rhPSMA-10.1 plus Degarelix
- Arms
- LeadIn: Treatment with 177Lu rhPSMA-10.1 · Experimental
- Enrollment
- 6 (estimated)
- Primary outcomes
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
- Efficacy will be assess by measuring the radiation dose to the tumor (dosimetries) and PSA assessment
- Sponsor
- M.D. Anderson Cancer Center with Blue Earth Therapeutics Ltd
- Start
- Mar 29, 2024
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06066437 · updated Nov 3, 2026